- |||||||||| pregnenolone methyl ether (MAP4343) / Mapreg
Preclinical, Journal: Chronic MAP4343 reverses escalated alcohol drinking in a mouse model of alcohol use disorder. (Pubmed Central) - Apr 4, 2023
Parallel analysis of tubulin post-translational modifications revealed lower ?-tubulin acetylation in the medial prefrontal cortex of CIE-withdrawn mice. Altogether, these data support the relevance of microtubules as a therapeutic target for the treatment of AUD.
- |||||||||| pregnenolone methyl ether (MAP4343) / Mapreg
Enrollment change, Trial withdrawal: MAP4343 Treatment for Alcohol Use Disorder (clinicaltrials.gov) - Mar 11, 2022
P2, N=0, Withdrawn,
Unknown status --> Recruiting | Trial completion date: Jun 2021 --> Dec 2023 | Trial primary completion date: Jun 2021 --> Sep 2023 N=50 --> 0 | Not yet recruiting --> Withdrawn
- |||||||||| pregnenolone methyl ether (MAP4343) / Mapreg
Trial completion date, Trial initiation date, Trial primary completion date: MAP4343 Treatment for Alcohol Use Disorder (clinicaltrials.gov) - Jul 8, 2020
P2, N=50, Not yet recruiting,
N=50 --> 0 | Not yet recruiting --> Withdrawn Trial completion date: Jul 2022 --> Dec 2022 | Initiation date: Jan 2020 --> Dec 2020 | Trial primary completion date: Jul 2022 --> Dec 2022
- |||||||||| Zulresso (brexanolone) / Sage Therapeutics, pregnenolone methyl ether (MAP4343) / Mapreg, allopregnanolone (LJPC-0712) / La Jolla Pharma
Journal: New therapeutic avenues for neurosteroids in psychiatric diseases (Pubmed Central) - May 19, 2020
On the other hand, their precursors and metabolites, such as pregnenolone (PREG), dehydroepiandrosterone (DHEA), their respective sulfate esters, pregnenolone sulfate (PREG-S) and DHEA sulfate (DHEA-S) and allopregnanolone (ALLOP), are defined as neurosteroids, but no corresponding nuclear receptors have been identified so far...It has been subsequently developed as Brexanolone and tested with success in phase III of clinical trials for the treatment of post-partum depression...An example of such innovative drugs is MAP4343, a synthetic derivative of PREG, which exhibits potent antidepressant-like efficacy in validated animal models. It is currently tested in depressed patients.
|
